Search results
14 lip 2024 · The 2 primary FDA-approved indications for ESA administration are 1) anemia secondary to chronic kidney disease and 2) chemotherapy-induced anemia in patients with cancer. The FDA approved the use of epoetin (1993) and darbepoetin (2002) for patients with chemotherapy-induced anemia.
9 sty 2019 · In 2010, ESMO released clinical practice guidelines for ESA use in treating anemia in cancer patients. The guidelines advised that Hb levels should not exceed 12 g/dL, and that ESAs should be carefully reconsidered in patients with a high risk of thromboembolic events, used with caution in liver disease, and not given to patients with ESA ...
4 kwi 2019 · ESAs (including biosimilars) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to < 10 g/dL. RBC transfusion is also an option.
When used, the goal of ESA therapy for patients with chemotherapy-induced anemia is to reduce RBC transfusion requirements. The FDA has indicated that ESAs should not be given to patients who are being treated for cancer
4 cze 2019 · Use of erythropoiesis-stimulating agents (ESAs) to manage anemia increases hemoglobin levels and reduces the need for RBC transfusions but increases the risk of thromboembolic events. 1, 2 Studies have also reported decreased survival, increased mortality during active study phase, and/or an increased risk of cancer progression or recurrence ...
10 kwi 2019 · A growing body of evidence suggests that adding iron to treatment with an ESA may improve hematopoietic response and reduce the likelihood of RBC transfusion. The biosimilar literature review suggested that biosimilars of epoetin alfa have similar efficacy and safety to reference products, although evidence in cancer remains limited.
the hematologic response to cancer treatment before considering an ESA. Particular caution should be exercised in the use of ESAs concomitant with treatment strategies and diseases where risk of thromboembolic complications is increased. In all cases, blood transfusion is a treatment option which should be considered. Type: Informal consensus
